Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia

Vanda Pharmaceuticals (NASDAQ: VNDA) has secured FDA approval for its new drug, BYSANTI™ (milsaperidone), marking a significant milestone for the biotech company. The treatment is approved for Bipolar I disorder manic episodes and schizophrenia symptoms in adults, strengthening Vanda’s position in the central nervous system (CNS) market. This announcement comes just weeks after the FDA cleared NEREUS™, giving Vanda its second regulatory win in under two months.

The FDA classified BYSANTI as a New Chemical Entity (NCE), a designation that provides extended market exclusivity and strong intellectual property protection. With patent protection extending through 2044, Vanda is shielded from generic competition for nearly two decades, creating a potential long-term revenue moat. Investors responded swiftly, sending VNDA stock up 44% in after-hours trading following the approval news.

Although BYSANTI is recognized as a new chemical entity, it is bioequivalent to iloperidone, marketed as Fanapt®. This connection allowed for a faster approval process due to its established safety and efficacy profile. Backed by more than 100,000 patient-years of real-world data, the drug offers physicians a familiar treatment option with a trusted safety record. BYSANTI works by modulating dopamine and serotonin pathways, and its strong alpha-adrenergic receptor binding may provide advantages for patients experiencing acute agitation and hostility.

Beyond its current indications, Vanda is evaluating milsaperidone as a potential treatment for major depressive disorder, with clinical results expected by late 2026. Positive data could significantly expand its addressable market and future revenue potential.

With analysts previously rating VNDA stock as “Sell” or “Hold,” this dual FDA approval momentum may prompt a reassessment of Vanda Pharmaceuticals’ growth outlook and long-term valuation.